Defined Duration 10 ETF

25.23

-0.2164-0.85%

Post-market: 25.280.0464+0.18%16:10 EDT

Volume:6K

Turnover:156.76K

Market Cap:68.64M

PE:- -

High:25.30

Open:25.24

Low:25.15

Close:25.45

52wk High:25.48

52wk Low:23.21

Shares:2.72M

Float Shares:2.72M

Volume Ratio:0.45

T/O Rate:0.23%

Dividend:0.86

Dividend Rate:3.40%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Dow Jones

·

Mar 09

Press Release: enGene Reports Full Year 2025 Financial Results and Provides Business Update

Dow Jones

·

Dec 23, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DDX"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DDX\",,,,,undefined,":{"symbol":"DDX","market":"US","secType":"STK","nameCN":"Defined Duration 10 ETF","latestPrice":25.2336,"timestamp":1782244800000,"preClose":25.45,"halted":0,"volume":6208,"hourTrading":{"tag":"盘后","latestPrice":25.28,"preClose":25.2336,"latestTime":"16:10 EDT","volume":6,"amount":151.4016,"timestamp":1782245404934,"change":0.0464,"changeRate":0.001839,"amplitude":0},"delay":0,"changeRate":-0.008502946954813366,"floatShares":2720000,"shares":2720000,"eps":0,"marketStatus":"Closed","change":-0.2164,"latestTime":"06-23 16:00:00 EDT","open":25.24,"high":25.3,"low":25.15,"amount":156757,"amplitude":0.005894,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782288000000},"marketStatusCode":5,"adr":0,"exchange":"CBOE","adjPreClose":25.45,"sharesOutstanding":2610000,"nav":25.4,"aum":69850000,"dividendRate":0.034002,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.28,"preClose":25.2336,"latestTime":"16:10 EDT","volume":6,"amount":151.4016,"timestamp":1782245404934,"change":0.0464,"changeRate":0.001839,"amplitude":0},"volumeRatio":0.452795},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DDX\",,,,,undefined,":{"symbol":"DDX","floatShares":2720000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.452795,"shares":2720000,"dividePrice":0.858,"high":25.3,"amplitude":0.005894,"preClose":25.45,"low":25.15,"week52Low":23.2089,"pbRate":"--","week52High":25.48,"institutionHeld":0,"latestPrice":25.2336,"eps":0,"divideRate":0.034002,"volume":6208,"delay":0,"ttmEps":0,"open":25.24,"prevYearClose":24.1815,"prevWeekClose":25.3844,"prevMonthClose":25.2202,"prevQuarterClose":24.2691,"fiveDayClose":25.3965,"twentyDayClose":25.0379,"sixtyDayClose":24.3466},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DDX\",params:#limit:5,,,undefined,":[{"date":"2026-03-30","symbol":"DDX","amount":0.090903,"announcedDate":"2026-03-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-30","defaultRemindTime":1774877400000,"name":"Defined Duration 10 ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-30","currency":"USD","dateTimestamp":1774843200000,"payDate":"2026-03-31"},{"date":"2025-12-30","symbol":"DDX","amount":0.3037028,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Defined Duration 10 ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2025-12-31"},{"date":"2025-09-29","symbol":"DDX","amount":0.2128678,"announcedDate":"2025-09-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-29","defaultRemindTime":1759152600000,"name":"Discipline Fund ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-29","currency":"USD","dateTimestamp":1759118400000,"payDate":"2025-09-30"},{"date":"2025-06-27","symbol":"DDX","amount":0.24909,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-27","defaultRemindTime":1751031000000,"name":"Discipline Fund ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-30","payableDate":"2025-06-27","currency":"USD","dateTimestamp":1750996800000,"payDate":"2025-06-30"},{"date":"2025-03-28","symbol":"DDX","amount":0.000548,"announcedDate":"2025-03-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-28","defaultRemindTime":1743168600000,"name":"Discipline Fund ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-31","payableDate":"2025-03-28","currency":"USD","dateTimestamp":1743134400000,"payDate":"2025-03-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DDX\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-05","value":0.2847293,"currency":"USD"},{"executeDate":"2022-12-27","recordDate":"2022-12-28","paymentDate":"2023-01-06","value":0.286258,"currency":"USD"},{"executeDate":"2023-03-29","recordDate":"2023-03-30","paymentDate":"2023-03-31","value":0.051555,"currency":"USD"},{"executeDate":"2023-06-28","recordDate":"2023-06-29","paymentDate":"2023-06-30","value":0.150981,"currency":"USD"},{"executeDate":"2023-09-27","recordDate":"2023-09-28","paymentDate":"2023-09-29","value":0.120251,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DDX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DDX\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618640488","title":"Press Release: enGene Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640488","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640488?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054000,"startTime":"0","endTime":"0","summary":"LEGEND pivotal cohort update planned for a spring 2026 medical conference. 12-month complete response data from LEGEND pivotal cohort expected in 2H 2026. Biologics License Application  submission for detalimogene planned for 2H 2026. Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028. enGene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2026, and provided a business update.\"As data from LEGEND's pivotal cohort in high-risk, BCG-unresponsive NMIBC continues to mature, we look forward to providing an update at a spring medical conference,\" said Ron Cooper, President and Chief Executive Officer, enGene. \"On the heels of our successful November follow-on offering, we entered 2026 in a position of financial strength and ready to execute. With RMAT and CDRP designations for detalimogene, we are in active dialogue with the FDA to ensure regulatory ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2237443382.USD","CMC","BK4139","BK4006","LABU","IE00B1BXHZ80.USD","IE00BZ1G4Q59.USD","IE00BFXG1179.USD","IE00BHPRN162.USD","BK4232","CR","LU0267386448.USD","BCG","LU2746668461.USD","R","LU0170899867.USD","LU2237443978.SGD","TRAE","LU0149725797.USD","HTGC","LU2237443622.USD","BK4588","BK4022","BK4161","LU2237443465.HKD","LU2746668974.SGD","IE00BKVL7J92.USD","LU1363072403.SGD","LU2237443549.SGD","DDX","LU2237443895.HKD","ENGN","LU0971096721.USD","BK4135","LU0882574139.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593583224","title":"Press Release: enGene Reports Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2593583224","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593583224?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:03","pubTimestamp":1766437380,"startTime":"0","endTime":"0","summary":"Completed enrollment in LEGEND's pivotal cohort with 125 patients in high-risk, BCG-unresponsive NMIBC with carcinoma in situ. Reported preliminary 6-month complete response rate (62%) in pivotal cohort patients enrolled under amended LEGEND protocol. enGene selected for FDA's CDRP Program to support CMC readiness. Cash and marketable securities plus proceeds from November financing expected to provide cash runway into 2H 2028. \"We are closing 2025 in a position of strength: enrollment in LEGEND's pivotal cohort is complete and the recent data update from the LEGEND pivotal cohort supports an emerging, competitive profile for the use of detalimogene as the first choice therapy in BCG-unresponsive NMIBC if approved,\" said Ron Cooper, President and Chief Executive Officer. \"With recent acceptance into FDA's CDRP program and a cash position of $342.4 million, extending our runway into the second half of 2028, we are entering the new year laser-focused on scaling our organization in prepar","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCG","IE00BKVL7J92.USD","LU2237443549.SGD","LU2237443978.SGD","BK4139","LU2237443895.HKD","LU2237443465.HKD","LU2746668461.USD","BK4232","IE00BFXG1179.USD","ENGN","DDX","BK4161","IE00BHPRN162.USD","LU2746668974.SGD","R","BK4022","TRAE","CMC","BK4135","LU0971096721.USD","LU0170899867.USD","LU2237443622.USD","LU0149725797.USD","LU0267386448.USD","LU2237443382.USD","IE00B1BXHZ80.USD","IE00BZ1G4Q59.USD","LU0882574139.USD","CR","LU1363072403.SGD","BK4006"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/DDX\",params:#limit:6,delay:false,,,undefined,":[]}}